FibroGen, Inc.

Equities

FGEN

US31572Q8087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.04 ^USD	+1.96%		-9.57%	+17.34%

Apr. 24	FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	CI
Apr. 15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN

FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 26, 2024 at 04:11 pm EST

FibroGen, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 147.75 million compared to USD 140.73 million a year ago. Net loss was USD 284.23 million compared to USD 293.65 million a year ago.

Basic loss per share from continuing operations was USD 2.92 compared to USD 3.14 a year ago.

Latest news about FibroGen, Inc.

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	CI
Faron Pharmaceuticals reappoints former finance chief on interim basis	Apr. 15	AN
Top Midday Decliners	Apr. 03	MT
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise	Apr. 03	MT
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	Apr. 02	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 12	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 12	MT
FibroGen Shares Jump After CEO Stock Purchase	Mar. 12	MT
FibroGen Names Deyaa Adib Chief Medical Officer	Mar. 11	MT
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer	Mar. 11	CI
Transcript : FibroGen, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
FibroGen regains rights to anemia drug from AstraZeneca	Feb. 26	RE
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (FGEN) FIBROGEN Reports Q4 Revenue $27.1M, vs. Street Est of $38.8M	Feb. 26	MT
FibroGen, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
FibroGen, Inc. Regains All Rights to Roxadustat from Astrazeneca in the United States and Other Astrazeneca Territories, Except China and South Korea	Feb. 26	CI
Transcript : FibroGen, Inc. - Special Call	Feb. 13
FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network?s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer	Jan. 25	CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Transcript : FibroGen, Inc., Q3 2023 Earnings Call, Nov 06, 2023	Nov. 06
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Earnings Flash (FGEN) FIBROGEN Reports Q3 Revenue $40.1M, vs. Street Est of $36.8M	Nov. 06	MT
FibroGen Names Interim Chief Executive Thane Wettig as CEO	23-10-06	MT
FibroGen, Inc. Appoints Thane Wettig as a Member of the Board	23-10-06	CI
FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer	23-10-06	CI

Chart FibroGen, Inc.

Duration

Period

More charts

Company Profile

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for FibroGen, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

1.04 USD

Average target price

1.75 USD

Spread / Average Target

+68.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FIBROGEN, INC.	+17.34%	103M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research